U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H15NO6
Molecular Weight 221.2078
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-ACETYLMANNOSAMINE

SMILES

CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=MBLBDJOUHNCFQT-WCTZXXKLSA-N
InChI=1S/C8H15NO6/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11/h2,5-8,11,13-15H,3H2,1H3,(H,9,12)/t5-,6-,7-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C8H15NO6
Molecular Weight 221.2078
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/25962821

N-acetylmannosamine (ManNAc), a hexosamine monosaccharide, is the first committed biological precursor of Neu5Ac. N-acetylmannosamine is being investigated as a potential treatment for GNE myopathy. N-acetylmannosamine has being reported to improve the cognitive function in aged animals. It has potential therapeutic application for cognitive dysfunction. N-acetylmannosamine is under investigation for GNE myopathy.

CNS Activity

Curator's Comment: N-acetylmannosamine (ManNAc) enhanced the hippocampal cell proliferation in mice. ManNAc had positive effects on the age-related brain dysfunction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: D-glucose phosphorylation
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2585 ng/mL
10 g single, oral
dose: 10 g
route of administration: Oral
experiment type: SINGLE
co-administered:
N-ACETYLMANNOSAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14161 ng × h/mL
10 g single, oral
dose: 10 g
route of administration: Oral
experiment type: SINGLE
co-administered:
N-ACETYLMANNOSAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
10 g single, oral
dose: 10 g
route of administration: Oral
experiment type: SINGLE
co-administered:
N-ACETYLMANNOSAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 g single, oral
Highest studied dose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources: Page: p.6, 20
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: myopathy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 6
Sources: Page: p.6, 20
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (50%)
Nausea (16.7%)
Sources: Page: p.6, 20
AEs

AEs

AESignificanceDosePopulation
Nausea 16.7%
10 g single, oral
Highest studied dose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources: Page: p.6, 20
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: myopathy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 6
Sources: Page: p.6, 20
Diarrhea 50%
10 g single, oral
Highest studied dose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources: Page: p.6, 20
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: myopathy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 6
Sources: Page: p.6, 20
Sourcing

Sourcing

Vendor/AggregatorIDURL

Sample Use Guides

GNE myopathy or hereditary inclusion body myopathy: liquid solution of N-acetylmannosamine - 3,000 mg, 6,000 mg, and 10,000 mg orally
Route of Administration: Oral
In Vitro Use Guide
50uM of N-acetylmannosamine caused a reduction of total capillary length by 75% of the values obtained for spheroids, which were not co-stimulated with sialic acid precursors.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:14:34 GMT 2023
Edited
by admin
on Sat Dec 16 05:14:34 GMT 2023
Record UNII
X80PR7P73R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
N-ACETYLMANNOSAMINE
Systematic Name English
2-ACETAMIDO-2-DEOXY-D-MANNOSE
Systematic Name English
D-MANNOSE, 2-(ACETYLAMINO)-2-DEOXY-
Systematic Name English
N-ACETYL-D-MANNOSAMINE
Systematic Name English
MANNAC
Common Name English
DEX-M74
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 303510
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
Code System Code Type Description
CHEBI
63153
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
DRUG BANK
DB12536
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
FDA UNII
X80PR7P73R
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
WIKIPEDIA
N-ACETYLMANNOSAMINE
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
CAS
3615-17-6
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
ECHA (EC/EINECS)
222-790-8
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
PUBCHEM
65150
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
CHEBI
17122
Created by admin on Sat Dec 16 05:14:34 GMT 2023 , Edited by admin on Sat Dec 16 05:14:34 GMT 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY